Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[99mTc]Tc-TECANT1 Feasibility Study in Neuroendocrine Neoplasms
NCT05871320Phase 1Completed
- Sponsor
- Jagiellonian University
- Start
- Dec 2022
- Primary completion
- Jun 2023
- Modality
- Peptides
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of [99mTc]Tc-TECANT1 in neuroendocrine neoplasms (NENs), sponsored by Jagiellonian University. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 14 days, Effective dose absorbed in critical organs at 2 days and 2 more. Started Dec 2022; status: completed.
02
Drugs
[99mTc]Tc-TECANT1
03
Conditions
neuroendocrine neoplasms (NENs)
Beyond the preview
Go deeper on NCT05871320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05871320.